Mangoceuticals, operating under the MangoRx and PeachesRx brands, has reported significant initial success for its newly launched all-inclusive injectable testosterone replacement therapy program priced at $99 per month. The program includes doctor visits, consultations, lab work and prescribed medication delivered through the company's telehealth platform.
Since launching in mid-December, month-over-month sales of the injectable TRT program have increased 336% while customer acquisition costs declined 54%. This performance reflects what the company described as growing demand for convenient hormone health solutions. The company expects TRT to serve as a primary growth driver as it seeks to expand its presence in the global TRT market, which is estimated to reach approximately $2.1 billion to $2.2 billion in 2025.
MangoRx is focused on developing a variety of men's health and wellness products and services via a secure telemedicine platform. The company currently offers pharmaceutical-based products specifically related to the treatments of erectile dysfunction, hair growth, hormone replacement therapies, and weight management. Interested consumers can use MangoRx's telemedicine platform for a smooth experience where prescription requests are reviewed by a licensed medical provider and, if approved, fulfilled and discreetly shipped through MangoRx's partner compounding pharmacy directly to the patient's doorstep.
The company's TRT program expansion comes alongside its oral formulations including PRIME by MangoRx powered by Kyzatrex. The significant sales growth and reduced customer acquisition costs suggest the $99 monthly pricing model is resonating with consumers seeking affordable, comprehensive hormone therapy options. This development positions Mangoceuticals to potentially capture market share in the rapidly growing telehealth and men's health sectors.
For more information about MangoRx's mission and other products, please visit https://www.MangoRx.com. Additional details about the press release can be found at https://ibn.fm/rq77U.
